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Background: The elderly, defined here as subjects aged  65 years, are among at-risk subjects for whom annual
influenza vaccination is recommended. For the 2018/19 season, three vaccine types are available for the elderly in
Italy: trivalent inactivated vaccine (TIV), adjuvanted TIV (aTIV) and quadrivalent inactivated vaccines (QIV).
No health technology assessment (HTA) of seasonal influenza vaccination in the elderly has previously been
conducted in Italy. Methods: An HTA was conducted in 2017 to analyze the burden of influenza illness, the
characteristics, efficacy, safety and cost-effectiveness of available vaccines and the related organizational and
ethical implications. This was then contextualized to the 2018/19 influenza season. Comprehensive literature
reviews/analyses were performed and a static mathematical model developed in order to address the above
issues. Results: In Italy, influenza is usually less common in the elderly than in other age-classes, but the burden
of disease is the highest; >10% of infected elderly subjects develop complications, and about 90% of all influenza-
related deaths occur in this age-class. All available vaccines are effective, safe and acceptable from an ethical
standpoint. However, aTIV has proved more immunogenic and effective in the elderly. Furthermore, from the
third payer’s perspective, aTIV is highly cost-effective and cost-saving in comparison with TIV and QIV, respectively.
Nevertheless, vaccination coverage needs to be improved. Conclusions: According to this HTA, aTIV appeared the
vaccine of choice in the elderly. HTA should be reapplied whenever new relevant data become available.
. .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . .
Introduction
Each winter, influenza affects 5–10% of the population, and isresponsible for considerable excess mortality. Since the virus
was isolated, prevention made great progress and several types of
vaccines were developed.1
Each year, the Italian Ministry of Health (MoH) issues recom-
mendations2 for seasonal influenza vaccination, identifying target
groups and vaccination coverage (VC) goals. In the 2018/19
season,2 three types of influenza vaccines are available in Italy:
trivalent inactivated vaccines (TIVs), adjuvanted TIV (aTIV) and
quadrivalent inactivated vaccines (QIVs). When compared with
TIVs and aTIV, which contain A(H1N1), A(H3N2) and a B strain
(belonging to Victoria or Yamagata lineage), QIVs may provide
broader protection by including B strains of both lineages. In
contrast, aTIV may provide better protection than unadjuvanted
vaccines, since it contains an adjuvant that significantly enhances
the immune response.2
In Italy, a health technology assessment (HTA)3 including a cost-
effectiveness analysis (CEA)4 of the use of aTIV in the elderly was first
conducted in 2016–17 by adopting a multidisciplinary policy-oriented
approach to evaluating the clinical, economic, organizational and
ethical implications of this health technology. Since then, major
regulatory changes occurred, with the intradermal TIV being perman-
ently withdrawn. Moreover, the latest MoH recommendations2 for the
first time advocated a preferential use of aTIV in the elderly aged 75
years and QIV in younger age-classes. Nevertheless, in the context of
Italian fiscal federalism, the procurement of single vaccine types is
inhomogeneous among Italian Regions.
In the original HTA report, we showed that aTIV could be
considered the best choice for the elderly. However, given the
above-mentioned regulatory and policy changes, and the fact that
we advocate continuous HTA, this article reports an update of our
previous findings.
Methods
The original HTA on the use of aTIV in the Italian elderly3 was
inspired by the EUnetHTA core model.5 It addressed several
domains: the health problem (epidemiology and burden of disease);
characteristics, immunogenicity/effectiveness and safety of available
vaccines; economic evaluation of available alternatives; and
organizational and ethical implications of influenza vaccination. The
study population was that of the elderly, defined as subjects aged 65
years, who are among the targets of annual influenza immunization.2
The full methodology and results of the first HTA report are reported
elsewhere.3 Here, we present an update of the original evaluation.
The health problem domain was addressed by implementing
different approaches. Specifically, all available national surveillance
systems were identified through the national influenza network
InfluNet6 and comprehensively assessed. The epidemiology of
influenza in Italy was characterized by analyzing Influenza-Like
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Illness (ILI) attack rates and data on virological surveillance.
Whenever possible, elderly specific data were extracted; the
atypical pandemic period (2009/10) was excluded from the analysis.
An analysis of the disease burden in terms of complications,
hospitalizations and mortality was then performed. First, routinely
collected administrative and surveillance data6,7 were retrieved and
analyzed. Second, a scoping review was performed by using the
following combination of MeSH and free-text terms in PubMed:
‘influenza’, ‘elderly’, ‘older’, ‘senior’, ‘burden’, ‘complic’,
‘hospital’, ‘death’, ‘Ital’. The search was widened to European
(first choice) and international evidence (by excluding the search
term ‘Ital’) in order to collect the data necessary to populate the
CEA and budget impact analysis (BIA) model. The subsequent
decision on which values to use was expert-driven.
As aTIV vaccination was the intervention of interest, a full systematic
review of the immunogenicity, efficacy/effectiveness, safety and
reactogenicity of this vaccine was carried out. Specifically, the
following aspects were comprehensively assessed: absolute and relative
immunogenicity, efficacy/effectiveness and safety. The full methodology
is reported in Supplementary Material S1. We did not perform a full
systematic review of the available comparators, as this was deemed un-
necessary and resource-consuming; indeed, the first TIVs have been in
use for several decades and an updated (last update 2018) systematic
Cochrane review on the matter is already available.8 We therefore con-
structed an overview of existing systematic reviews and meta-analyses
dealing with the immunogenicity, efficacy, effectiveness and safety of
TIVs and QIVs in the elderly by applying the following search
strategy: ((‘influenza’[Title/Abstract] AND vaccine[Title/Abstract]
AND ‘systematic review’[Title/Abstract])) AND (‘elderly’[Title/
Abstract] OR (‘older’[Title/Abstract] AND adult[Title/Abstract])).
The search was performed in PubMed, Embase and Cochrane Library.
The CEA considered all the vaccine types available to the Italian
elderly in the 2018/19 season, namely TIV, aTIV and QIV. The CEA
was performed in accordance with the CHEERS (Consolidated Health
Economic Evaluation Reporting Standards) statement;9 full method-
ology details can be found in Supplementary Material S2. Briefly, a
static decisional-tree model was adopted for the whole cohort of Italian
elderly. The study was conducted from the third payer’s perspective
within the time-frame of a single average influenza season. The BIA
evaluated the sustainability of the preferential use of aTIV for all
subjects aged 75 years (as per recent guidelines)2 in comparison
with the observed 2018/19 market shares of single vaccines.
Regarding organizational implications, an analysis of Italian vaccin-
ation recommendations, VC and procedures of vaccine distribution were
analyzed. Concerning the strategies implemented in order to pursue VC
targets, we examined the latest update (2018) of the Cochrane review10
on interventions to increase influenza vaccination rates among the
community-dwelling elderly and performed a rapid literature overview
on PubMed by using the following search terms: ‘vaccin’, ‘influenza’,
‘recommend’, ‘distribut’, ‘organ’, ‘strateg’, ‘procedur’.
Ethical analysis was performed by means of the so-called ‘triangular
model’, a well-recognized regulatory approach.11 This model places the
human being at the centre of the ethical reflection and of the judgement
of lawfulness/unlawfulness. The analytical scheme is divided into three
phases: (i) collection and analysis of data on the technology (cognitive
phase); (ii) evaluation of how the technology relates to the person’s
integral good (evaluation phase) in terms of risk/benefit ratio; quality of
life; respect for patients’ autonomy; obtainment of informed consent;
and possibility of ensuring equal access; (iii) elaboration of the final
ethical opinion, with identification of any ethical problem that
decision-makers should take into account (prescriptive phase).
Results
Health problem
In Italy, ILI epidemics occur annually, their incidence and duration
varying widely in terms of both seasons and age-classes
(Supplementary Material S3). ILI epidemics generally start 1–3
weeks later in the elderly than in the general population. The
average 18-season (from 1999/00 to 2017/18) ILI peak incidence
was about half as high in the elderly as in the general population
(4.6 vs. 9.6ø). Over this 18-season period, the average detection
rate of type A viruses in the general population was markedly
higher than that of type B (76 vs. 24%), with influenza type B
predominating over type A in only four (22%) of the 18 seasons.
Most type A detections belonged to the H3N2 subtype
(Supplementary Material S4). It also emerged that, unfortu-
nately, the national surveillance network does not routinely
report the (sub)type distribution by age-class. To address this
issue, we recently conducted a systematic review12 of the com-
parative distribution of A and B viruses in the elderly, but were
able to identify only one study from Italy.13 In that study,13 most
virus B detections (94.8%) were concentrated in the <65-year
age-group, while only 5.2% of detections involved subjects aged
65 years.
The literature on the burden of influenza in Italy is rather limited;
some relevant data, such as the probability of developing complica-
tions and being hospitalized, are missing. Sessa et al.14 described
6057 patients who were followed up by their general practitioners
(GPs) for ILI in the 1998/99 season, 35.1% of whom (and 57.8% of
the 709 patients aged 65 years) developed 1 complication, par-
ticularly upper respiratory tract infections (42.0%) and bronchitis
(42.0%). About 0.4% (1.2% of patients with complications) were
hospitalized. However, the results of this Italian study differ substan-
tially from what has been reported in the international literature and
supported by national experts. For instance, in a widely cited large-
scale (n = 141 293 ILI patients) six-season UK study,15 the probabil-
ity of developing 1 complication was about three times lower
(10.9%), with high-risk elderly subjects displaying greater probabil-
ity than their low-risk counterparts (12.6 vs. 9.7%). This difference
between the two studies was probably due to the single-season time-
frame and relatively small sample size of the Italian study.
Regarding data on influenza-attributed hospitalization, no
elderly-specific Italian data were found. According to experts’
opinion, one of the most comprehensive sources of such data is
the US inFLUenza hospitalization SURVeillance NETwork.16 The
cumulative hospitalization rate in the elderly varied from a
minimum of 30.2 per 100 000 in 2011/12 to a maximum of 438.1
in 2017/18. However, these figures may be underestimated by about
five times, owing to under-detection due to underutilization of
influenza testing and its sensitivity pattern in the elderly.17
According to death certificates, on average about 90% of influenza
deaths in Italy occur in the elderly,7 and there is a positive relation-
ship between the age of elderly sub-cohorts and mortality (figure 1).
However, death certificates underestimate the real number of deaths
for several reasons, mainly because they do not consider deaths due
to influenza complications (e.g. pneumonia or worsening heart
failure, which are often reported as the initial cause of death).
Rizzo et al.18 overcame this problem by estimating excess deaths
due to pneumonia and influenza [14.1 (range 0–38) per 100 000]
and all causes [98.9 (range 0–107) per 100 000] in Italy across 32
influenza seasons.
Influenza vaccines available in the 2018/19 season
Table 1 reports the main characteristics of influenza vaccines
available in the 2018/19 season.
Previously published systematic reviews and meta-analyses8,19–23
generally highlighted suboptimal immunogenicity, efficacy and ef-
fectiveness of TIVs in the elderly. In particular, a large meta-analysis
by Goodwin et al.19 revealed that the elderly had significantly lower
odds of being seroconverted against all (sub)types than young
adults. In the Cochrane review8 the absolute efficacy of TIVs
against laboratory-confirmed influenza (LCI) was 58% (95% CI:
34–73%), while re-assessment21 of these findings provided an
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estimate of 49% (95% CI: 33–62%). Regarding the ability of TIVs to
protect against hospitalization- and mortality-related proxy
outcomes, estimates are inconsistent.8
For what concerns QIV, an immunogenicity meta-analysis by
Moa et al.24 showed that QIV was non-inferior to TIV with regard
to shared strains, but superior for the fourth B strain, which was
not included in TIV. However, a recent meta-regression by Beyer
et al.20 underlined that pre-seasonal immunity is the main driver
of the impact of B-lineage mismatch on TIV vaccine effectiveness
(VE); thus, QIV would have a significant advantage over TIV in
younger age-classes, while in the elderly the benefit would be
rather limited.20 No absolute efficacy/effectiveness data on QIV
could be established.
Table 2 reports the main characteristics of aTIV; the full results of
the systematic review are presented in Supplementary Material S1.
Briefly, in the elderly, aTIV was found to be more immunogenic
than TIV versus both homologous and drifted strains and generally
more effective than both TIV and QIV, its absolute VE being
relatively high regardless of the influenza-related outcome.
From the safety standpoint, all available vaccines may be deemed
acceptable. When compared with unadjuvanted vaccines, aTIV may
cause more solicited adverse events (especially local); these, however,
were judged acceptable from the risk-benefit viewpoint (table 3;
Supplementary Material S1).
Economic evaluation of aTIV
Head-to-head comparison of TIV and aTIV showed that the latter
was highly cost-effective. In contrast, QIV was dominated by aTIV
(table 3). Probabilistic sensitivity analysis showed that, compared
with TIV, aTIV was cost-saving/-effective (ICER < E30 000/
QALY) in 76.4% of simulations.
In comparison with the observed (2018/19 season) market
situation, a strategy in which aTIV is preferentially given to all
75-years old would be associated with 9699, 1 014, 311 and 12
influenza episodes, complications, hospitalizations and deaths less,
respectively. This alternative strategy would also save about E0.53
million in vaccination campaigns, resulting in total budget savings of
over E1.67 million (table 3).
The complete results of the CEA and BIA are shown in
Supplementary Material S2.
Organizational and ethical implications of the use of
aTIV
In Italy, annual influenza vaccination is available free-of-charge to
the elderly and to subjects at risk or of particular social value; the
main organizational challenge is achieving VC goals. Despite the
Italian MoH recommendations (minimum and optimal VC of 75
and 95%, respectively),2 VC in the elderly population remains rather
Figure 1 Influenza-attributable deaths (death certificates) in the elderly (65 years) and non-elderly (<65 years) Italian population (A) and
within the elderly population (B)
Table 1 Influenza vaccines available in Italy in 2018/19 season2
Characteristics TIV QIV aTIV
Component A(H1N1)pdm09 + + +
A(H3N2) + + +
B(Yam)  + 
B(Vic) + + +
Adjuvant   MF59
Age indication 6 months 6 months 65 years
Notes In children (0.5–9 years) and adolescents (10–17 years) use of QIV
should be preferred, given the high impact of influenza B and
potential lineage mismatch. If QIV is not available, TIV must be
used. In at-risk adults (18–64 years) and healthcare workers,
QIV should also be preferred. Pregnant women, who are at
higher risk from influenza A(H1N1)pdm09, could receive either
TIV or QIV
TIV, aTIV and QIV are recommended for people
aged 65 years. However, given the high
impact of influenza A(H3N2) in subjects aged
75 years and evidence of the greater ef-
fectiveness of aTIV in this population, aTIV
should provide higher protection than either
TIV or QIV
Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season 3
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low (about 53%), with huge interregional differences.25
Furthermore, procedures of vaccine distribution and administration
vary among Regions.2
In order to achieve the recommended VC, new strategic and
organizational measures are needed. These must involve the whole
health-planning chain, from decision-makers to GPs, who play a key
role in linking patients’ health needs with adequate public health
surveillance and protection.
Effective strategies, already described in previous studies, could
also be promoted in Italy. These include new approaches to vaccin-
ation campaigns, especially in target groups like the elderly,2,26 the
creation of regional lists of elderly patients based on disease codes of
exemption from payment, in order to identify high-risk subjects to
be actively called,2 and promoting vaccination in hospital.27,28 The
Cochrane review on interventions to increase influenza VC in the
community-dwelling elderly10 identified three main pillars that can
be effective: increasing community demand (e.g. reminders, recalls,
counselling), enhancing vaccination access (e.g. alternative places of
vaccination) and provider/system-based interventions (e.g. GPs’
gratification). Similar interventions have been judged to be transfer-
able to the Italian setting.
With regard to ethical issues, the data reveal that the risk/benefit
ratio of influenza vaccination in the elderly is positive. Several
studies have shown that aTIV has a higher level of immunogenicity
Table 2 The main characteristics, immunogenicity, effectiveness and safety of the adjuvanted trivalent influenza vaccinea
Characteristics Description
General Influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1

(aTIV) is indicated for active immunization against
influenza in the elderly (65 years), especially for those with an increased risk of associated complications.
One 0.5 ml dose of the vaccine is composed of:
 influenza virus surface antigens (haemagglutinin and neuraminidase) of strains belonging to A(H1N1), A(H3N2) and B
(15mcg of haemagglutinin of each strain) recommended by the World Health Organization;
 MF59C.1 adjuvant is composed of: 9.75 mg squalene, 1.175 mg polysorbate 80, 1.175 mg sorbitan trioleate, 0.66 mg
sodium citrate, 0.04 mg citric acid, water for injections;
 It may contain traces of eggs, such as ovalbumin or chicken proteins, kanamycin and neomycin sulphate, formaldehyde,
cetyltrimethylammonium bromide and barium sulphate, which are used during the manufacturing process.
Immunogenicity When compared with non-vaccination, aTIV is highly immunogenic against A(H1N1), A(H3N2) and B vaccine-like strains,
regardless the serological outcome (e.g. geometric mean titre and geometric mean ratio, seroconversion and seroprotection
rates). Analogously, the absolute immunogenicity against drifted/heterologous strains is generally high, especially against
those belonging to A(H3N2).
Compared with unadjuvanted TIVs (relative immunogenicity) aTIV has generally been found more immunogenic against
vaccine-like A(H1N1), A(H3N2) and B strains. Indeed, several meta-analyses have shown a statistical superiority of aTIV,
independently from the (sub)type considered. aTIV has also proved clearly superior to TIV against drifted A(H3N2) strains in
both haemagglutinin inhibition and microneutralization tests.
Effectiveness The absolute effectiveness of aTIV has proved relatively high, with some variability of estimates, depending on influenza-
related outcome, being 58% (95% CI 5–82%) against LCI [72% (95 CI 2–93%) when considering only community-dwelling
elderly], 87% (95% CI 35–97%) against hospitalizations for acute coronary syndrome and 93% (95% CI 52–99%) against
hospitalizations for cerebrovascular events. Regarding hospitalizations for pneumonia/influenza, the absolute effectiveness
of aTIV was 48% (95% CI 20–66%), 69% (95% CI 29–66%) and 49% (95% CI 30–60%) in influenza seasons 2002/03, 2004/05
and 2011/12, respectively. Moreover, it was as high as 94% (95% CI 47–100%) against ILI among the institutionalized elderly.
When compared with unadjuvanted TIVs (relative effectiveness), aTIV was found to be 63% (95% CI 4–86%), 25% (95% CI 2–
43%) and 34% (95% CI 18–47%) more effective against LCI, hospitalizations for pneumonia/influenza and influenza-like
illness, respectively. aTIV was recently shown to be 3.3% (P < 0.05) more effective than QIV in preventing influenza hospital
encounters in US Medicare beneficiaries (65 years, n > 13 million) in the 2017/18 season.
Safety According to the summary of product characteristics, very common (1/10) undesirable effects include tenderness, injection site
pain, fatigue, myalgia, headache; common (1/100–<1/10) effects are redness, swelling, ecchymosis, induration, nausea,
diarrhoea, vomiting, sweating, arthralgia, fever, malaise and shivering. Most of these are mild or moderate and resolve
spontaneously within 1–2 days.
In randomized clinical trials (solicited adverse events) aTIV was generally found more reactogenic than unadjuvanted TIVs,
especially for what concerns local events. In contrast, in an integrated analysis of 64 clinical trials, unsolicited adverse events
were less common with aTIV than with TIVs.
Co-administration with
other vaccines
aTIV can be safely co-administered with both 23-valent pneumococcal polysaccharide and 13-valent pneumococcal conjugate
vaccines, without significant immunologic inference.
a: The full set of references is available in Supplementary Material S1.
Table 3 Base-case results of the cost-effectiveness and budget impact analyses of the influenza vaccines available to the Italian elderly in
the 2018/19 season
CEA
Strategy Total costs, E  Total costs, E Effectiveness, QALY  Effectiveness, QALY104 ICER, E/QALY
TIV 10.92 – 8.960839 – –
aTIV 11.35 0.43 8.960935 0.96 4527
QIV 14.21 2.86 8.960864 Negative Dominated
BIA
Scenario Vaccination costs, E  Vaccination costs, E Event costs, E  Event costs, E Total costs, E  Total costs, E
Currenta 83 571 644 532 596 15 723 809 1 139 182 99 295 453 1 671 778
Alternativeb 83 039 048 14 584 627 97 623 675
a: Elderly specific market shares, as per Regional allotments for 2018/19 influenza season.
b: A scenario in which all subjects aged 75 years receive aTIV, while those aged 65–74 years receive QIV, as per Ministerial Circular2.
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and effectiveness in the elderly and a safety profile similar to that of
unadjuvanted vaccines. The reduction of morbidity and the possible
preservation of self-sufficiency could have considerable impact on
the subject’s quality of life. Respect for the patient’s autonomy
requires that informed consent be obtained. For this reason, it is
important to organize personalized consultations before vaccine ad-
ministration and to evaluate the patient’s ability to understand the
information provided and to express his/her consent. Finally, in the
interests of the common good, access to vaccination should be
ensured for the entire target population. Decision-makers must
bear in mind all of the above-mentioned aspects and also organize
adequate pharmacovigilance.
Discussion
This HTA update highlighted some important aspects for the
decision-making process regarding influenza vaccination in the
elderly. We underlined that influenza is highly age-dependent;
while its incidence is higher among younger age-classes, influenza-
related hospitalizations and deaths mostly involve the elderly.
Available vaccines are effective, safe and ethically acceptable. In the
elderly, aTIV seems to be the most effective vaccine and appeared to
be the best choice. This is in line with the recent statement by the
Public Health England and Joint Committee on Vaccination and
Immunization29 on the preferential use of aTIV in 65-years olds.
However, decision-makers should also consider how to implement
preventive interventions effectively promoting activities aimed at
reaching target populations and increasing VC.
With respect to resource allocation, economic evidence on
influenza vaccination in the elderly is still insufficient. A 2017
systematic review30 of economic evaluations of influenza vaccination
in the elderly identified only eight items, most of which suggested
the cost-effectiveness of vaccination vs. non-vaccination.
Analogously, a systematic review of Italian HTA and economic
studies31 found that vaccinating the elderly against influenza yields
a positive benefit/cost ratio in comparison with non-vaccination.
The added value of our work is that it analyzed different vaccine
types. A paper32 specifically compared aTIV with TIV and QIV in
the USA and concluded that using aTIV in the elderly could yield
greater clinical and economic benefits. In contrast, previous Italian
CEAs of aTIV33,34 compared aTIV only with TIV and non-vaccin-
ation. In any case, for what concerns the comparison of aTIV vs.
TIV, our results are comparable to previous Italian findings33,34 in
that aTIV proved cost-effective. On the other hand, in previous
research, aTIV was also found dominant over TIV. This can
probably be explained by the fact that previous research used ILI
as an influenza-related proxy, while the present CEA used LCI,
which is more conservative.
However, the limited comparative effectiveness data may be an
issue in interpreting our results and some uncertainty persists, in
particular with respect to the comparison between aTIV and QIV. In
fact, our analysis was primarily based on the evidence20 that QIV
does not bring a significant advantage to the elderly. This seems to
be confirmed by a recent multi-season analysis35 showing a substan-
tial cross-lineage protection of trivalent vaccines and by a US study36
where the absolute VE of TIV and QIV were 38 and 18% in 2016/17
season. Considering that the price and relative VE are the main
drivers of economic outcomes, a re-evaluation should be done
once the price of either vaccine is dropped and/or new comparative
effectiveness data are available.
According to MacKean et al.,37 Health Technology Reassessment
is ‘a structured, evidence-based assessment of the clinical, social,
ethical and economic effects of a technology currently used in the
healthcare system, to inform optimal use of that technology in
comparison to its alternatives’. This study fits this definition and
is one of the first Italian attempts to meet the urgent need for
continuity in the HTA process.
Two principal shortcomings could impact the overall interpret-
ation of results. First, it was not deemed feasible to conduct
systematic reviews in all the HTA domains. Alternative methods,
including umbrella and scoping reviews and the appraisal of
existing systematic reviews, were adopted in order to mitigate this
shortcoming. Second, the pool of Italy and elderly specific original
research on several influenza domains was very limited and,
therefore, international findings were borrowed to feed the
economic models.
Nevertheless, this update sheds lights on the appropriateness of
the use of technologies as the only way to optimize and strengthen
the value of public health interventions.38 This research is fostering
the development of recommendations on vaccination policies based
on different inputs, with a view to improving the use of existing
vaccines.39
In this regard, there is a need to enhance existing surveillance
systems, to perform robust large-scale population-based studies to
track the natural history of influenza among Italians and to further
investigate social, cultural and economic factors playing a role in
patients’ attitudes and behaviours in order to deliver additional, up-
to-date information to guide future choices concerning resources
allocation.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 As health technology assessment (HTA) is a continuous
process, seasonal influenza vaccines should be re-assessed
each year as soon as new relevant data become available or
regulatory or policy changes occur.
 Influenza vaccination is recommended in the elderly. Three
different vaccine types are available in Italy for the 2018/19
season. However, fiscal federalism makes their use heteroge-
neous across the country and necessitates evidence of the
appropriateness of their use.
 This HTA update revealed that the adjuvanted trivalent
influenza vaccine could be adopted in the Italian elderly in
preference to unadjuvanted trivalent and quadrivalent
vaccines, and that adherence to the latest MoH recommen-
dations on its use in all subjects aged 75 years could save
money.
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